Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.56
+0.15 (2.77%)
At close: Oct 3, 2025, 4:00 PM EDT
5.55
-0.01 (-0.18%)
After-hours: Oct 3, 2025, 4:18 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$582,526
Market Cap
304.12M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38 | -4 | -9.52% |
Dec 31, 2023 | 42 | -34 | -44.74% |
Dec 31, 2022 | 76 | 11 | 16.92% |
Dec 31, 2021 | 65 | 24 | 58.54% |
Dec 31, 2020 | 41 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CADL News
- 7 hours ago - Candel Therapeutics to Present at the SITC 2025 Annual Meeting - GlobeNewsWire
- 4 days ago - Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 16 days ago - Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 26 days ago - Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha
- 4 weeks ago - Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors - Seeking Alpha
- 4 weeks ago - Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D. - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire